Cisplatin Injection, Solution
FDA Label NDC 0703-5748

39 label sections · Submitted to the FDA by Teva Parenteral Medicines, Inc. · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Teva Parenteral Medicines, Inc. for the product Cisplatin (NDC 0703-5748). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding warning: nephrotoxicity, peripheral neuropathy, nausea and vomiting and myelosuppression, 1.1 advanced testicular cancer, 1.2 advanced ovarian cancer, 1.3 advanced bladder cancer, 2.1 hydration and anti-emetic treatment, 2.2 advanced testicular cancer, 2.3 advanced ovarian cancer, 2.4 advanced bladder cancer, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

* Please review the disclaimer below.